Cardiovascular effects of drugs used to treat Alzheimer's disease

Drug Safety

Volumn 37, Issue 6, 2014, Pages 391-395

  Howes, Laurence Guy ^a  

^a GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; FAINTNESS; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SURVIVAL; SYSTEMATIC REVIEW; TORSADE DES POINTES; ADVERSE DRUG REACTION; ANIMAL; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CARDIOVASCULAR SYSTEM; CHOLINESTERASE INHIBITORS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS;

EID: 84901846006     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0161-z     Document Type: Review

References (34)

1. Galimberti D, Scarpini E. Progress in Alzheimer's disease in the last year. J Neurol. 2013;260:1936-41.
2. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Disord. 2013;35(5-6):239-48.
3. Anand P, Singh B. A review of cholinesterase inhibitors for Alzheimers' disease. Arch Pharm Res. 2013;36(4):375-99.
4. Birks J. Cholinesterase inhibitors for Alzheimers' disease. Cochrane Database Syst Rev. 2006;1:CD005593.
5. 3H MK-801 at therapeutic concentrations in post mortem human frontal cortex. Eur J Pharmacol. 1989;166:589-90.
6. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger U, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115cell systems in a non-competitive manner. Neurosci Lett. 2001;306(1-2):81-4. (Pubitemid 32524303)
7. Buisson B, Bertrand D. Open channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol. 1998;53(3):555-63. (Pubitemid 28162880)
8. 2 high receptors. Synapse. 2008;62(2):149-53.
9. Mosqueda-Garcia R, Furlan R, Tank J, Fernandez-Violante R. The elusive pathophysiology of neurally mediated syncope. Circulation. 2000;102(23):2898- 906.
10. Newby VJ, Kenny RA, McKeith IG. Donezepil and cardiac syncope: case report. Int J Geriatr Psychiat. 2004;19:1110-2. (Pubitemid 39496942)
11. Bordier P, Lanusse S, Garrigue S, Reynard C, Robert F, Gencel L, Lafitte A. Causes of syncope in patients with Alzheimers disease treated with donezepil. Drugs Aging. 2005;22(8):687-94. (Pubitemid 41138980)
12. Bordier P, Garrigue S, Lanusse S, Margaine J, Robert F, Gencel L, Lafitte A. Cardiovascular effects and risk of syncope related to donezepil in patients with Alzheimers' disease. CNS Drugs. 2006;20(5):411-7. (Pubitemid 43763740)
13. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand ST, Rochon PA. Syncope and its' consequences in patients with dementia receiving cholinesterase inhibitors: a population based cohort study. Arch Intern Med. 2009;169(9):867-73.
14. Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donezepil: tolerability and safety in Alzheimers' disease. Int J Clin Pract. 2002;56:710-7. (Pubitemid 35414512)
15. Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, Shulman KI, Anderson GM, Wodchis WP, Rochon PA. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11(2):e274-85. (Pubitemid 46333124)
16. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc. 2009;57:1997-2003.
17. Parke-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalizations for bradycardia. PLOS Med. 2009;6(9):e1000157.
18. Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E. Cardiac safety of donezepil in elderly patients with Alzheimers' disease. Intern Med. 2012;51(6):575-8.
19. Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol. 2002;42(5):558-68. (Pubitemid 34438555)
20. Isik AT, Bozoglu E, Yay A, Soysal P, Atescan U. Which cholinesterase inhibitor is safest for the heart in elderly patients with Alzheimers' disease? Am J Alzheimers Dis Other Dem. 2012;27(3):171-4.
21. Leitch A, McGinness P, Wallbridge D. Calculate the QT interval in patients taking drugs for dementia. BMJ. 2007;335(7619):557. (Pubitemid 47477688)
22. Fisher AA, Davis MW. Prolonged QT interval, syncope and delirium with galantamine. Ann Pharmacother. 2008;42(2):278-83. (Pubitemid 351238578)
23. Tanaka A, Kuga S, Hiramatsu Y. Donepezil induced adverse events of cardiac rhythm: 2 case reports of atrioventricular block and torsades de pointes. Intern Med. 2009;48(14):1219-23.
24. Takaya T, Okamoto M, Yodoi K, Hata K, Kijima Y, Nakajima H, Nishikawa Y, Kita T, Seo T, Kawashima S. Torsades de pointes with QT prolongation related to donepezil use. J Cardiol. 2009;54(3):507-11.
25. Poluzzi E, Rashi E, Moretti U, DePonti F. Drug induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18(6):512-8.
26. Inanago K, Ichiki T, Miyazaki R, Takeda K, Hashimoto T, Matsuura H, Sunagawa K. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis. 2010;213(1):52-8.
27. Handa T, Katare RG, Kakimuma Y, Arikawa M, Ando M, Sasaguri S, Yamasaki F, Sato T. Anti-Alzheimers' drug, donepezil, markedly improves long term survival after chronic heart failure in mice. J Card Fail. 2009;15(9):805-11.
28. Li M, Zheng C, Kawada T, Inagaki M, Uemura K, Shishido T, Sugimachi M. Donepezil markedly improves long-term survival in rats with chronic heart failure after extensive myocardial infarction. Circ J. 2013;77(10):2519-25.
29. Kubo T, Sato T, Noguchi T, Kitaoka H, Yamasaki F, Kamimura N, Shimodera S, Iiama T, Kumadai N, KakinumaY, Diedrich A, Jordan J, Robertson D, Doi YL. Influences of donepezil on cardiovascular system: possible therapeutic benefits for heart failure. Donepezil Cardiac Test Registry (DOCTER) study. J Cardiovasc Pharmacol. 2012;60(3):310-4.
30. Nordstrom P, Religa D, Wimo A, Winbald B, Eriksdotter M. The use of acetyl cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimers' disease. Eur Heart J. 2013;34(33):2585-91.
31. Sato T, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, Robertson D, Diedrich A. The effect of donepezil on cardiovascular mortality. Clin Pharmacol Ther. 2010;88(3):335-8.
32. Gallini A, Sommet A, Montastrue JL. French PharmacoVigilance network: does memantine induce bradycardia? Pharmacoepidemiol Drug Saf. 2008;17(9):877-81.
33. Igeta H, Suzuki Y, Motegi T, Sasaki A, Yokoyama Y, Somega T. Deterioration of donepezil-induced PR prolongation after co-administration of memantine in a patient with AD. Gen Hosp Psychiatry. 2013;31:1873-4.
34. Fosbol EL, Pederson ED, Holm E, Gislason GH, Zhang Y, Curtis LH, Kober L, Iwata I, Torp-Pedersen GH, Setoguchi S. Comparative cardiovascular safety of dementia medications: a cross national study. J Am Geriatr Soc. 2012;6(12):2283-9.